sST2 and Heart Failure—Clinical Utility and Prognosis
New parameters and markers are constantly being sought to help better assess patients with heart failure (HF). ST2 protein has gained interest as a potential biomarker in cardiovascular disease. It is known that the IL-33/ST2L system belongs to the cardioprotective pathway, which prevents the fibros...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/9/3136 |
| _version_ | 1797602284093308928 |
|---|---|
| author | Magdalena Dudek Marta Kałużna-Oleksy Jacek Migaj Filip Sawczak Helena Krysztofiak Maciej Lesiak Ewa Straburzyńska-Migaj |
| author_facet | Magdalena Dudek Marta Kałużna-Oleksy Jacek Migaj Filip Sawczak Helena Krysztofiak Maciej Lesiak Ewa Straburzyńska-Migaj |
| author_sort | Magdalena Dudek |
| collection | DOAJ |
| description | New parameters and markers are constantly being sought to help better assess patients with heart failure (HF). ST2 protein has gained interest as a potential biomarker in cardiovascular disease. It is known that the IL-33/ST2L system belongs to the cardioprotective pathway, which prevents the fibrosis, hypertrophy, and apoptosis of cardiomyocytes and also inhibits the inflammatory response. Soluble ST2 (sST2) is involved in the immune response and secreted in response to the mechanical overload of the myocardium, thus providing information on the processes of myocardial remodeling and fibrosis. A total of 110 hospitalized patients diagnosed with heart failure with reduced ejection fraction (HFrEF) were included in the study. Clinical and biochemical parameters were studied. During the follow-up, 30.9% patients died and 57.3% patients reached the composite endpoint. Using ROC curves, the reference cut-off point for sST2 was determined to be 45.818 pg/mL for all-cause deaths. Significantly higher concentrations of inflammatory parameters and natriuretic peptides were found in the group of patients with higher sST2 concentrations. sST2 protein is an independent risk factor for all-cause deaths of patients with HFrEF. |
| first_indexed | 2024-03-11T04:14:57Z |
| format | Article |
| id | doaj.art-2207822035c14dec9f9d907e81686be9 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T04:14:57Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-2207822035c14dec9f9d907e81686be92023-11-17T23:11:12ZengMDPI AGJournal of Clinical Medicine2077-03832023-04-01129313610.3390/jcm12093136sST2 and Heart Failure—Clinical Utility and PrognosisMagdalena Dudek0Marta Kałużna-Oleksy1Jacek Migaj2Filip Sawczak3Helena Krysztofiak4Maciej Lesiak5Ewa Straburzyńska-Migaj61st Department of Cardiology, Poznań University of Medical Sciences, 61-848 Poznań, Poland1st Department of Cardiology, Poznań University of Medical Sciences, 61-848 Poznań, Poland1st Department of Cardiology, Poznań University of Medical Sciences, 61-848 Poznań, Poland1st Department of Cardiology, Poznań University of Medical Sciences, 61-848 Poznań, PolandDepartment of Cardiology, University Hospital in Opole, 45-401 Opole, Poland1st Department of Cardiology, Poznań University of Medical Sciences, 61-848 Poznań, Poland1st Department of Cardiology, Poznań University of Medical Sciences, 61-848 Poznań, PolandNew parameters and markers are constantly being sought to help better assess patients with heart failure (HF). ST2 protein has gained interest as a potential biomarker in cardiovascular disease. It is known that the IL-33/ST2L system belongs to the cardioprotective pathway, which prevents the fibrosis, hypertrophy, and apoptosis of cardiomyocytes and also inhibits the inflammatory response. Soluble ST2 (sST2) is involved in the immune response and secreted in response to the mechanical overload of the myocardium, thus providing information on the processes of myocardial remodeling and fibrosis. A total of 110 hospitalized patients diagnosed with heart failure with reduced ejection fraction (HFrEF) were included in the study. Clinical and biochemical parameters were studied. During the follow-up, 30.9% patients died and 57.3% patients reached the composite endpoint. Using ROC curves, the reference cut-off point for sST2 was determined to be 45.818 pg/mL for all-cause deaths. Significantly higher concentrations of inflammatory parameters and natriuretic peptides were found in the group of patients with higher sST2 concentrations. sST2 protein is an independent risk factor for all-cause deaths of patients with HFrEF.https://www.mdpi.com/2077-0383/12/9/3136sST2heart failurebiomarkerHFrEF |
| spellingShingle | Magdalena Dudek Marta Kałużna-Oleksy Jacek Migaj Filip Sawczak Helena Krysztofiak Maciej Lesiak Ewa Straburzyńska-Migaj sST2 and Heart Failure—Clinical Utility and Prognosis Journal of Clinical Medicine sST2 heart failure biomarker HFrEF |
| title | sST2 and Heart Failure—Clinical Utility and Prognosis |
| title_full | sST2 and Heart Failure—Clinical Utility and Prognosis |
| title_fullStr | sST2 and Heart Failure—Clinical Utility and Prognosis |
| title_full_unstemmed | sST2 and Heart Failure—Clinical Utility and Prognosis |
| title_short | sST2 and Heart Failure—Clinical Utility and Prognosis |
| title_sort | sst2 and heart failure clinical utility and prognosis |
| topic | sST2 heart failure biomarker HFrEF |
| url | https://www.mdpi.com/2077-0383/12/9/3136 |
| work_keys_str_mv | AT magdalenadudek sst2andheartfailureclinicalutilityandprognosis AT martakałuznaoleksy sst2andheartfailureclinicalutilityandprognosis AT jacekmigaj sst2andheartfailureclinicalutilityandprognosis AT filipsawczak sst2andheartfailureclinicalutilityandprognosis AT helenakrysztofiak sst2andheartfailureclinicalutilityandprognosis AT maciejlesiak sst2andheartfailureclinicalutilityandprognosis AT ewastraburzynskamigaj sst2andheartfailureclinicalutilityandprognosis |